Gene therapy upstart raises $7.2M; Alkermes adds an Alzheimer's drug to its pipeline;

@FierceBiotech: From FierceDrugDelivery: UPDATED: @US_FDA agrees to review $ENDP's inside-the-cheek pain drug. More | Follow @FierceBiotech

@JohnCFierce: Interested in ADCs and VC cash? Mersana grabs a $35M round, posts ex-Millennium chief Protopapas at helm. Article | Follow @JohnCFierce

@DamianFierce: The fake Immunovaccine release reads like a parody of bio stock pumping. Image | Follow @DamianFierce

> A new gene therapy company based in Milan, Genenta Science, has raised $7.2 million from venture investors. The startup was cofounded by Luigi Naldini, director of the San Raffaele-Telethon Institute for Gene Therapy. Release

> Alkermes ($ALKS) is adding a new drug for its pipeline that aims to prove it can treat agitation in patients with Alzheimer's and other CNS conditions. ALKS 7119 is set to go into the clinic later this year, an event that the transatlantic biotech plans to roll out to analysts at its annual investors' day today. Release

> GlaxoSmithKline ($GSK) is handing Isis ($ISIS) a $15 million milestone payment in exchange for advancing ISIS-TTR, a new drug for familial amyloid polyneuropathy (FAP). Release

Medical Device News

@FierceMedDev: Startup Akili partners with nonprofit Autism Speaks to test video game. News | Follow @FierceMedDev

@VarunSaxena2: ICYMI: More lawsuits planned as infected endoscope safety scare grows. More | Follow @VarunSaxena2

> J&J confirms $1.9B sale of Cordis unit to Cardinal Health, ending months of speculation. Story

> FDA approves Actavis intrauterine device to prevent pregnancy. Article

> Startup Akili partners with nonprofit Autism Speaks to test video game. More

Pharma News

@FiercePharma: Oculus leaps into animal health with 6 new skin and eye products. FierceAnimalHealth story | Follow @FiercePharma

@EricPFierce: ICYMI from FiercePharmaManufacturing: FDA problems continue to pile up at Wockhardt Indian plant banned from shipping to the US. Article | Follow @EricPFierce

@CarlyHFierce: ICYMI: Bayer counts on consumer health, pharma growth to power 2015. Story | Follow @CarlyHFierce

> AstraZeneca director pushing to tie exec pay to big growth promises. Report

> Post-Novartis deal, GSK's top dog in vaccines, consumer health. Now what? Story

> GSK deal's done. Now, Novartis has to deliver on cancer-growth pledge. More

Biotech IT News

> RainDance files for $60M IPO. Item

> Novo Nordisk set to rake in up to $335M from IT unit IPO. Report

> Eccrine bags seed funding for Air Force-developed sweat sensor. News

> Analyst casts doubt on Big Data potential of Covance-LabCorp merger. Story

> H3 hooks up with Foundation Medicine for data-driven oncology R&D. Article

CRO News

> Charles River embraces discovery in management shake-up. News

> Catalent beefs up its European network for clinical supplies. Story

> Enteris gets into contract manufacturing with new plant. Item

> INC Research soars in its first post-IPO quarter. Report

> Icon rides a revenue leap into another growth year. Article

Animal Health News

> Bayer to close animal health plant in St. Joseph, MO; sell off some product lines. More

> Aratana regains dog lymphoma drug from Lilly for 'great price,' say analysts. Story

> Purina faces lawsuit over dogs allegedly sickened by Beneful. Item

> Oculus leaps into animal health with 6 new skin and eye products. Article

> Parnell records strong sales growth, stays focused on arthritis approval. Report